Rashmi Khanal
Hematology & Oncology · Philadelphia, PANPI 1841595634
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.4% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $491 and has fallen 68.8% since, to $153 in 2025. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 52 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$239
- Johnson & Johnson$231
- Novartis$171
- Daiichi Sankyo Inc.$134
- Astellas Pharma US Inc$84
- Bristol Myers Squibb$71
- plus $384 from 13 others
Across 25 payments — averaging $3671.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$75K
- Bristol Myers Squibb$14K
- Iovance Biotherapeutics, Inc.$2K
What the payments were for
- Food & beverage$1,21592%
- Education$1008%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 3 | $239 |
| Johnson & Johnson | 8 | $231 |
| Novartis | 8 | $171 |
| Daiichi Sankyo Inc. | 6 | $134 |
| Astellas Pharma US Inc | 3 | $84 |
| Bristol Myers Squibb | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Sanofi | 3 | $55 |
| Incyte Corporation | 3 | $42 |
| Pfizer | 2 | $38 |
| Gilead | 1 | $38 |
| Genentech USA, Inc. | 2 | $33 |
| Lilly USA, LLC | 1 | $20 |
| Merck | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Morphosys, US Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$114
How this compares
$1,315 in reported general payments places this provider in the 50th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 13 | $191 |
| Acyclovir | 20 | $118 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.